Market Closed -
Borsa Istanbul
08:38:01 14/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
12.13
TRY
|
+0.41%
|
|
-4.34%
|
-15.41%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
65.14
|
41.06
|
83.75
|
1,241
|
951.4
|
1,299
|
Enterprise Value (EV)
1 |
49.8
|
35.51
|
80.91
|
1,247
|
843.9
|
1,219
|
P/E ratio
|
15.7
x
|
69.9
x
|
15
x
|
19.1
x
|
8.31
x
|
4.62
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.69
x
|
2.01
x
|
5
x
|
5.39
x
|
2.48
x
|
15.1
x
|
EV / Revenue
|
1.3
x
|
1.73
x
|
4.83
x
|
5.41
x
|
2.2
x
|
14.2
x
|
EV / EBITDA
|
11.9
x
|
-3.28
x
|
-52.6
x
|
23.1
x
|
8.49
x
|
-996
x
|
EV / FCF
|
-98.4
x
|
-3.38
x
|
-14.2
x
|
-42.5
x
|
22.1
x
|
-13.1
x
|
FCF Yield
|
-1.02%
|
-29.6%
|
-7.02%
|
-2.36%
|
4.52%
|
-7.62%
|
Price to Book
|
1.2
x
|
0.71
x
|
0.97
x
|
8.26
x
|
3.04
x
|
2.18
x
|
Nbr of stocks (in thousands)
|
54,922
|
54,922
|
84,012
|
95,415
|
1,00,000
|
1,00,000
|
Reference price
2 |
1.186
|
0.7477
|
0.9969
|
13.01
|
9.514
|
12.99
|
Announcement Date
|
12/03/18
|
11/03/19
|
04/03/20
|
11/03/21
|
11/03/22
|
13/03/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
38.45
|
20.47
|
16.77
|
230.4
|
384.3
|
86.03
|
EBITDA
1 |
4.177
|
-10.82
|
-1.539
|
54.03
|
99.37
|
-1.224
|
EBIT
1 |
3.046
|
-11.71
|
-2.767
|
52.48
|
95.42
|
-7.79
|
Operating Margin
|
7.92%
|
-57.19%
|
-16.5%
|
22.77%
|
24.83%
|
-9.06%
|
Earnings before Tax (EBT)
1 |
4.358
|
-2.227
|
3.952
|
87.99
|
147.4
|
302.5
|
Net income
1 |
4.158
|
0.6012
|
4.423
|
60.93
|
114.5
|
281.1
|
Net margin
|
10.81%
|
2.94%
|
26.38%
|
26.44%
|
29.78%
|
326.78%
|
EPS
2 |
0.0757
|
0.0107
|
0.0666
|
0.6811
|
1.145
|
2.811
|
Free Cash Flow
1 |
-0.5059
|
-10.5
|
-5.682
|
-29.36
|
38.11
|
-92.91
|
FCF margin
|
-1.32%
|
-51.28%
|
-33.89%
|
-12.74%
|
9.92%
|
-108%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
38.35%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
33.29%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/18
|
11/03/19
|
04/03/20
|
11/03/21
|
11/03/22
|
13/03/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
5.11
|
-
|
-
|
Net Cash position
1 |
15.3
|
5.56
|
2.85
|
-
|
107
|
79.6
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
0.0945
x
|
-
|
-
|
Free Cash Flow
1 |
-0.51
|
-10.5
|
-5.68
|
-29.4
|
38.1
|
-92.9
|
ROE (net income / shareholders' equity)
|
7.58%
|
-0.59%
|
6.29%
|
61.6%
|
49.8%
|
59%
|
ROA (Net income/ Total Assets)
|
3.07%
|
-11.3%
|
-2.11%
|
18.5%
|
14.7%
|
-0.75%
|
Assets
1 |
135.4
|
-5.305
|
-209.5
|
329.4
|
776.4
|
-37,318
|
Book Value Per Share
2 |
0.9900
|
1.050
|
1.030
|
1.570
|
3.130
|
5.950
|
Cash Flow per Share
2 |
0.2800
|
0.1100
|
0.1500
|
0.1800
|
1.580
|
0.3100
|
Capex
1 |
0.32
|
2.22
|
5.19
|
16
|
21.4
|
12.7
|
Capex / Sales
|
0.83%
|
10.84%
|
30.96%
|
6.93%
|
5.58%
|
14.8%
|
Announcement Date
|
12/03/18
|
11/03/19
|
04/03/20
|
11/03/21
|
11/03/22
|
13/03/23
|
|
1st Jan change
|
Capi.
|
---|
| -15.41% | 3.75Cr | | -1.11% | 8.94TCr | | +2.76% | 4.07TCr | | -12.32% | 3.28TCr | | +52.41% | 2.5TCr | | -17.39% | 1.53TCr | | -42.45% | 1.16TCr | | -10.48% | 1.15TCr | | +6.14% | 898.19Cr | | -7.72% | 822.67Cr |
Biopharmaceuticals
|